Ketamine as augmentation for the treatment of major depression and suicidal risk in advanced cancer: Case report. Issue 1 (February 2020)

• Record Type: Journal Article
• Authors: Rodríguez-Mayoral, Oscar; Pérez-Esparza, Rodrigo; Domínguez-Ocadio, Georgina; Allende-Pérez, Silvia
• Is Part Of: Palliative & supportive care. Volume 18:Issue 1(2020)
• Page Start: 110
• Page End: 112
• Publication Date: 2020-02
• Subjects: Palliative care, -- advanced cancer, -- depression, -- ketamine, -- suicidal risk; Palliative treatment -- Great Britain -- Periodicals; 616.029
• DOI: 10.1017/S1478951519000580
• Languages: English
• ISSNs: 1478-9515

Abstract

Abstract: Objective: Major depressive disorder (MDD) is common in patients diagnosed with advanced cancer (AC), with a prevalence of 16.5%. It is associated with great disability and worsened quality of life, increased number and intensity of physical symptoms, and lower survival. It is the main factor for the presence of suicidal ideation. Antidepressants show modest efficacy, and response requires several weeks. Ketamine has demonstrated a fast and robust antidepressant effect in subanesthetic doses. This effect may prove useful in patients with AC, MDD, and suicidal risk. Method: We report a case of a patient with advanced cervical cancer who presented with uncontrollable pain, MDD, and a suicide attempt. Result: A 39-year-old woman diagnosed with cervical cancer stage IVB presented to the Emergency Department after a suicide attempt by hanging. Upon evaluation by the palliative care psychiatrist, she reported intense pain, unresponsive to analgesics, and had a history of persistent suicidal ideation. Antidepressant treatment was started (sertraline 50mg/d) after a single dose of ketamine hydrochloride IV (0.5 mg/kg) was administered. Treatment response was measured using the Brief Edinburgh Depression Scale before and after the intervention. The depressive symptoms decreased by 17% on day 1, 39% on day 3, and 72% on day 17. Significance of results: This case report shows ketamine's efficacy as an augmentation agent alongside conventional antidepressant treatment in patients with AC. Moreover, it shows rapid response in suicidal ideation that has not been achieved with treatment as usual. More clinical trials are needed to support the potential benefit and safety of ketamine in patients with AC, MDD, and persisting suicidal ideation.